These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35184993)

  • 1. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
    Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
    Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
    Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR
    PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Induction Management in Patients With Left-Sided
    Parisi A; Cortellini A; Venditti O; Filippi R; Salvatore L; Tortora G; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Fulgenzi C; Lombardi P; Roselló Keränen S; Depetris I; Giampieri R; Morelli C; Di Marino P; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Patruno L; D'Orazio C; Ficorella C; Ferri C; Porzio G
    Front Oncol; 2021; 11():712053. PubMed ID: 34778029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
    Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
    J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
    Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
    Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
    Raimondi A; Nichetti F; Stahler A; Wasan HS; Aranda E; Randon G; Kurreck A; Meade AM; Díaz-Rubio E; Niger M; Stintzing S; Palermo F; Trarbach T; Prisciandaro M; Sommerhäuser G; Fisher D; Morano F; Pietrantonio F; Modest DP
    Eur J Cancer; 2023 Sep; 190():112945. PubMed ID: 37441940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
    Papamichael D; Lopes GS; Olswold CL; Douillard JY; Adams RA; Maughan TS; Van Cutsem E; Venook AP; Lenz HJ; Heinemann V; Kaplan R; Bokemeyer C; Chibaudel B; Grothey A; Yoshino T; Zalcberg J; De Gramont A; Shi Q
    Eur J Cancer; 2022 Mar; 163():1-15. PubMed ID: 35033994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis.
    Petrelli F; Cherri S; Ghidini M; Tomasello G; Ghidini A; Zaniboni A
    Dig Liver Dis; 2024 Feb; 56(2):242-247. PubMed ID: 37369616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
    Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
    Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
    Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis.
    Mastrantoni L; Beccia V; Caira G; Trovato G; Calegari MA; Basso M; Salvatore L; Pozzo C; Tortora G; Bria E; Orlandi A
    Crit Rev Oncol Hematol; 2023 Nov; 191():104106. PubMed ID: 37659764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
    Hsieh MC; Wu CF; Chen CW; Shi CS; Huang WS; Kuan FC
    Sci Rep; 2018 Feb; 8(1):2047. PubMed ID: 29391418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.